Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iofetamine SCHEMBL1534301 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| Iofetamine SCHEMBL11151697 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| Iofetamine SCHEMBL8973644 | 0.98 | APEX1 (1.00) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| Iofetamine SCHEMBL7755724 | 0.98 | APEX1 (1.00) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| Iofetamine SCHEMBL9860677 | 0.89 | CYP1A2 (0.80) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| Iofetamine SCHEMBL9860681 | 0.89 | CYP1A2 (0.80) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| SCHEMBL20862299 | 0.83 | CYP1A2 (0.70) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| SCHEMBL18211455 | 0.81 | CYP1A2 (0.68) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| SCHEMBL11265489 | 0.81 | CYP2D6 (0.68) | CYP1A2CYP2D6APEX1PMP22SLC6A4 | |
| SCHEMBL23986761 | 0.79 | CYP1A2 (0.66) | CYP1A2CYP2D6APEX1PMP22SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1004321-B1 | STABLE RADIOACTIVE MEDECINE | DAIICHI RADIOISOTOPE LAB (JP) | 2003-02-26 | — | — | EP | claimed |
| EP-0485479-B1 | PERFLUORO-T-BUTYL-CONTAINING COMPOUNDS FOR USE IN FLUORINE-19 NMR AND/OR MRI | UNIV JOHNS HOPKINS (US) | 1996-04-03 | — | — | EP | claimed |
| EP-0011858-B1 | RADIOIODINE CONTAINING AMINES, THEIR PREPARATION AND THEIR USE AS BRAIN IMAGING AGENTS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-05-18 | — | — | EP | claimed |
| CN-111393306-B | Apparatus for synthesizing radioiodinated compound | 日本医事物理股份有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-111393306-A | Apparatus for synthesizing radioiodinated compound | 日本医事物理股份有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-9129373-B2 | Apparatus for evaluating the accuracy of a SPECT or PET system using a phantom filled with a radioisotope | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20130251226-A1 | APPARATUS FOR EVALUATING ACCURACY OF MEASUREMENT | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2013-09-26 | — | — | US | disclosed |
| EP-1363954-B1 | POLYMER PRECURSORS OF RADIOLABELED COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | UNIV WESTERN ONTARIO (CA) | 2012-10-17 | — | — | EP | disclosed |
| US-20100274052-A1 | PREPARATION OF RADIOLABELLED HALOAROMATICS VIA POLYMER-BOUND INTERMEDIATES | University of West Ontario | 2010-10-28 | — | — | US | disclosed |
| US-7658910-B2 | Preparation of radiolabelled haloaromatics via polymer-bound intermediates | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2010-02-09 | — | — | US | disclosed |
| EP-1197227-B9 | METHOD OF THE ADMINISTRATION OF DRUGS HAVING BINDING AFFINITY WITH PLASMA PROTEIN AND PREPARATION TO BE USED IN THE METHOD | NIHON MEDIPHYSICS CO LTD (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-0335918-A1 | DIAGNOSTIC OR RADIOTHERAPEUTIC COMPOSITION COMPRISING A HYDROGEN CONTAINING COMPOUND | Mallinckrodt Diagnostica (Holland) B.V. (NL) | 1989-10-11 | — | — | EP | disclosed |
| WO-1989001342-A2 | DIAGNOSTIC OR RADIOTHERAPEUTIC COMPOSITION COMPRISING A HYDROGEN CONTAINING COMPOUND | MALLINCKRODT, INC. (US) | 1989-02-23 | — | — | WO | disclosed |
| US-4771059-A | CENTRAL NERVOUS SYSTEM | UNIVERSITY OF FLORIDA (US) | 1988-09-13 | — | — | US | disclosed |
| EP-0174342-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. | UNIV FLORIDA (US) | 1986-03-19 | — | — | EP | disclosed |
| EP-0165630-A2 | Method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radioiodinated, aromatic or heteroaromatic compound, as well as a kit for preparing a diagnostic composition on the basis of this compound | MALLINCKRODT, INC.(a Missouri corporation) (US) | 1985-12-27 | — | — | EP | disclosed |
| WO-1985003937-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1985-09-12 | — | — | WO | disclosed |
| EP-0011858-B1 | RADIOIODINE CONTAINING AMINES, THEIR PREPARATION AND THEIR USE AS BRAIN IMAGING AGENTS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-05-18 | — | — | EP | disclosed |
| US-4360511-A | Amines useful as brain imaging agents | MEDI-PHYSICS, INC. (US) | 1982-11-23 | — | — | US | disclosed |
| EP-0011858-A1 | Radioiodine containing amines, their preparation and their use as brain imaging agents | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274052-A1 | PREPARATION OF RADIOLABELLED HALOAROMATICS VIA POLYMER-BOUND INTERMEDIATES | MPI, HDHD5, IPO5 | CYP1A2 35/4885CYP2D6 212/4885APEX1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.